Michael Hassell, DO
Physical Medicine & Rehabilitation · Arlington, TXNPI 1285093450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Nevro Corp. at 40.2% of the total. Reporting peaked in 2021 at $302 and has fallen 91.9% since, to $25 in 2022.
Across 18 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$151
- IBSA Pharma Inc.$63
- Si-bone, Inc.$49
- Biodelivery Sciences International, Inc.$35
- Virtus Pharmaceuticals LLC$27
- Collegium Pharmaceutical, Inc.$13
- plus $37 from 3 others
Across 1 payment — averaging $4287.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Scilex Pharmaceuticals Inc.$4K
What the payments were for
- Food & beverage$376100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 3 | $151 |
| IBSA Pharma Inc. | 5 | $63 |
| Si-bone, Inc. | 2 | $49 |
| Biodelivery Sciences International, Inc. | 2 | $35 |
| Virtus Pharmaceuticals LLC | 2 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Orthogenrx Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
How this compares
$376 in reported general payments places this provider in the 60th percentile of 651 physical medicine & rehabilitation providers in Texas.
See all physical medicine & rehabilitation providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 194 | $6,705 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 85 | $3,435 |
| BelsomraSuvorexant | 11 | $2,364 |
| Tramadol Hcl | 112 | $1,705 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 21 | $780 |
| Tizanidine Hcl | 26 | $645 |
| Morphine Sulfate ErMorphine Sulfate | 20 | $602 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Arlington
- Gerard FranciscoHouston$364K
- Jose UrquidezAustin$332K
- Gireesh ShardaDallas$172K
- Suzanne ManziHouston$143K
- Cindy IvanhoeHouston$111K
- Chad McNeilTyler$64K
- Sheng LiHouston$44K
- Mary RussellShenandoah$37K
- Randall WolcottLubbock$31K
- Ryan WhitmerCollege Station$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.